Catalog No.: PC-44628Not For Human Use, Lab Use Only.
Senexin-A is a selective inhibitor of CDK8 (IC50=0.28 uM) and CDK19, inhibits CDK8 and CDK19 ATP site binding with Kd50 of 0.83 uM and 0.31 uM, respectively.
Senexin-A is a selective inhibitor of CDK8 (IC50=0.28 uM) and CDK19, inhibits CDK8 and CDK19 ATP site binding with Kd50 of 0.83 uM and 0.31 uM, respectively.
Senexin-A inhibits only p21-induced transcription but not other biological effects of p21, inhibits β-catenin-dependent transcription in HCT116 colon carcinoma cells.
Senexin-A suppresses damage-induced tumor-promoting paracrine activities of tumor cells and normal fibroblasts.
Senexin-A reverses the increase in tumor engraftment and serum mitogenic activity in mice pretreated with doxorubicin.
